Inhibition of CYP2D6-mediated Tramadol O-demethylation in Methadone but Not Buprenorphine Maintenance Patients

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2012 Feb 29

PMID 22369095

Citations 5

Authors

Janet K Coller

Jennifer R Michalakas

Heather M James

Aaron L Farquharson

Joel Colvill

Jason M White

Andrew A Somogyi

Affiliations

Soon will be listed here.

Abstract

What Is Already Known About This Subject: Management of pain in opioid dependent individuals is problematic due to numerous issues including cross-tolerance to opioids. Hence there is a need to find alternative analgesics to classical opioids and tramadol is potentially one such alternative. Methadone inhibits CYP2D6 in vivo and in vitro. We aimed to investigate the effect of methadone on the pathways of tramadol metabolism: O-demethylation (CYP2D6) to the opioid-active metabolite M1 and N-demethylation (CYP3A4) to M2 in subjects maintained on methadone or buprenorphine as a control.

What This Study Adds: Compared with subjects on buprenorphine, methadone reduced the clearance of tramadol to active O-desmethyl-tramadol (M1) but had no effect on N-desmethyltramadol (M2) formation. Similar to other analgesics whose active metabolites are formed by CYP2D6 such as codeine, reduced formation of O-desmethyltramadol (M1) is likely to result in reduced analgesia for subjects maintained on methadone. Hence alternative analgesics whose metabolism is independent of CYP2D6 should be utilized in this patient population.

Aims: To compare the O- (CYP2D6 mediated) and N- (CYP3A4 mediated) demethylation metabolism of tramadol between methadone and buprenorphine maintained CYP2D6 extensive metabolizer subjects. METHODS Nine methadone and seven buprenorphine maintained subjects received a single 100 mg dose of tramadol hydrochloride. Blood was collected at 4 h and assayed for tramadol, methadone, buprenorphine and norbuprenorphine (where appropriate) and all urine over 4 h was assayed for tramadol and its M1 and M2 metabolites.

Results: The urinary metabolic ratio [median (range)] for O-demethylation (M1) was significantly lower (P= 0.0002, probability score 1.0) in the subjects taking methadone [0.071 (0.012-0.103)] compared with those taking buprenorphine [0.192 (0.108-0.392)], but there was no significant difference (P= 0.21, probability score 0.69) in N-demethylation (M2). The percentage of dose [median (range)] recovered as M1 was significantly lower in subjects taking methadone compared with buprenorphine (0.069 (0.044-0.093) and 0.126 (0.069-0.187), respectively, P= 0.04, probability score 0.19), M2 was significantly higher in subjects taking methadone compared with buprenorphine (0.048 (0.033-0.085) and 0.033 (0.014-0.049), respectively, P= 0.04, probability score 0.81). Tramadol was similar (0.901 (0.635-1.30) and 0.685 (0.347-1.04), respectively, P= 0.35, probability score 0.65).

Conclusions: Methadone inhibited the CYP2D6-mediated metabolism of tramadol to M1. Hence, as the degree of opioid analgesia is largely dependent on M1 formation, methadone maintenance patients may not receive adequate analgesia from oral tramadol.

Citing Articles

An Investigation of O-Demethyl Tramadol/Tramadol Ratio for Cytochrome P450 2D6 Phenotyping: The CYTRAM Study.

De La Gastine B, Percevault S, Varin L, Richard N, Fobe F, Plaud B Pharmaceutics. 2022; 14(10).

PMID: 36297612 PMC: 9611900. DOI: 10.3390/pharmaceutics14102177.

[Interaction of opioid analgesics at the level of biotransformation].

Petri H, Grandt D Schmerz. 2016; 30(6):519-525.

PMID: 27439327 DOI: 10.1007/s00482-016-0141-6.

The Pharmacogenetics of Tramadol.

Lassen D, Damkier P, Brosen K Clin Pharmacokinet. 2015; 54(8):825-36.

PMID: 25910878 DOI: 10.1007/s40262-015-0268-0.

The anti-addiction drug ibogaine and the heart: a delicate relation.

Koenig X, Hilber K Molecules. 2015; 20(2):2208-28.

PMID: 25642835 PMC: 4382526. DOI: 10.3390/molecules20022208.

New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

Soyka M Subst Abuse Rehabil. 2015; 6:1-14.

PMID: 25610012 PMC: 4293937. DOI: 10.2147/SAR.S45585.

References

Alford D, Compton P, Samet J . Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006; 144(2):127-34. PMC: 1892816. DOI: 10.7326/0003-4819-144-2-200601170-00010. View

Stamer U, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A . Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003; 105(1-2):231-8. DOI: 10.1016/s0304-3959(03)00212-4. View

Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy R . Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003; 289(18):2370-8. DOI: 10.1001/jama.289.18.2370. View

Shiran M, Chowdry J, Rostami-Hodjegan A, Ellis S, Lennard M, Iqbal M . A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2003; 56(2):220-4. PMC: 1884285. DOI: 10.1046/j.1365-2125.2003.01851.x. View

Doverty M, Somogyi A, White J, Bochner F, Beare C, Menelaou A . Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 2001; 93(2):155-163. DOI: 10.1016/S0304-3959(01)00306-2. View

Gillen C, Haurand M, Kobelt D, Wnendt S . Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000; 362(2):116-21. DOI: 10.1007/s002100000266. View

Driessen B, Reimann W, GIERTZ H . Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. Br J Pharmacol. 1993; 108(3):806-11. PMC: 1908052. DOI: 10.1111/j.1476-5381.1993.tb12882.x. View

Newcombe R . Confidence intervals for an effect size measure based on the Mann-Whitney statistic. Part 2: asymptotic methods and evaluation. Stat Med. 2005; 25(4):559-73. DOI: 10.1002/sim.2324. View

Newcombe R . Confidence intervals for an effect size measure based on the Mann-Whitney statistic. Part 1: general issues and tail-area-based methods. Stat Med. 2005; 25(4):543-57. DOI: 10.1002/sim.2323. View

10.

Zhang L, Zhang Y, Zhao P, Huang S . Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009; 11(2):300-6. PMC: 2691466. DOI: 10.1208/s12248-009-9106-3. View

11.

Paar W, Frankus P, DENGLER H . The metabolism of tramadol by human liver microsomes. Clin Investig. 1992; 70(8):708-10. DOI: 10.1007/BF00180294. View

12.

Laugesen S, Enggaard T, Pedersen R, Sindrup S, Brosen K . Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther. 2005; 77(4):312-23. DOI: 10.1016/j.clpt.2004.11.002. View

13.

Paar W, Poche S, Gerloff J, DENGLER H . Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol. 1997; 53(3-4):235-9. DOI: 10.1007/s002280050368. View

14.

Doran C, Shanahan M, Mattick R, Ali R, White J, Bell J . Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003; 71(3):295-302. DOI: 10.1016/s0376-8716(03)00169-8. View

15.

Huxtable C, Roberts L, Somogyi A, Macintyre P . Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care. 2011; 39(5):804-23. DOI: 10.1177/0310057X1103900505. View

16.

Subrahmanyam V, Renwick A, Walters D, Young P, Price R, Tonelli A . Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001; 29(8):1146-55. View

17.

Jensen M, Foster D, Upton R, Grant C, Martinez A, Somogyi A . Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica. 2007; 37(4):441-57. DOI: 10.1080/00498250701251126. View

18.

Pedersen R, Damkier P, Brosen K . Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther. 2005; 77(6):458-67. DOI: 10.1016/j.clpt.2005.01.014. View

19.

Carroll C, Walsh S, Bigelow G, Strain E, Preston K . Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp Clin Psychopharmacol. 2006; 14(2):109-20. DOI: 10.1037/1064-1297.14.2.109. View

20.

Foster D, Morton E, Heinkele G, Murdter T, Somogyi A . Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: application to a pharmacokinetic study in a methadone maintained.... Ther Drug Monit. 2006; 28(4):559-67. DOI: 10.1097/00007691-200608000-00012. View